Company news
Ultragenyx Pharmaceutical Inc. news in 2019
Ultragenyx Pharmaceutical Inc.'s news releases, calls and decks from 2019, newest first.
Ultragenyx Announces Sale of Future European Royalties on Crysvita® (burosumab) for $320 Million to Royalty Pharma
December 17, 2019
Ultragenyx Reports Third Quarter 2019 Financial Results and Corporate Update
November 4, 2019
Ultragenyx Announces FDA Accepts New Drug Application for UX007 (triheptanoin) for Treatment of Long-chain Fatty Acid Oxidation Disorders
October 13, 2019
Ultragenyx and Kyowa Kirin Announce U.S. FDA Approves Label Update for Crysvita® (burosumab) for the Treatment of X-Linked Hypophosphatemia (XLH)
September 29, 2019
Ultragenyx and Kyowa Kirin Announce Intent to Submit Supplemental Biologics License Application to U.S. FDA for Crysvita® (burosumab) in Tumor-Induced Osteomalacia (TIO)
September 9, 2019